somewordstoolate/Q2CRBench-3 huggingface dataset:
Reference: Hori M, Matsumoto M, Tanahashi N, et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 2013; 77: 632-638.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. American Heart Journal 2018; 198: 169-177.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics:
Reference: Hijazi Z, Alexander JH, Li Z, et al. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention Insights From the AUGUSTUS Trial. Circulation 2021; 143: 1215-1223.
Study design: Randomized Controlled Trial
Guideline evidence base: 2024 KDIGO CKD
Study characteristics: